Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients
| Status: | Archived |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | December 2008 |
| End Date: | December 2015 |
A Biologic Efficacy Study of Dasatinib, a Multi-Targeted Tyrosine Kinase, in Locally Advanced Triple-Negative Breast Cancer Patients Developing Effective Therapies for Er-Negative Breast Cancer Using Genomics and Proteomics: Project 3
We want to learn if dasatinib will make triple negative breast cancers smaller. We also hope
that we can learn more about what makes triple negative breast cancers grow. We believe this
information will help us to predict which patients will benefit from taking this drug or
other drugs like it.
This study is a "neoadjuvant study", which means that it is only open to women who have not
had any treatment for their breast cancer. Neoadjuvant studies allow the study doctor to
look at how the cells in your cancer change after taking the study medication. This will
help us to understand whether or not dasatinib is an effective treatment for breast cancer.
It will also help us to learn more about triple negative breast cancer and how to treat it.
Women who have been recently diagnosed with a type of breast cancer called "triple
negative", and have not yet received any type of treatment (surgery, radiation therapy,
etc.) for breast cancer are among the patient population this study will seek. "Triple
negative" means breast cancer is not estrogen receptor positive (ER+), progesterone receptor
positive (PgR+) or human epidermal growth factor receptor positive (HER2+). Some types of
breast cancers "overexpress" one or more of these receptors. "Overexpress" means that the
cancer cells have too many of these receptors. ER and PgR are hormone receptors that are
located on some types of breast cancer cells. When these receptors are present, the hormones
estrogen and progesterone are able to tell cancer cells to grow and divide.
This kind of breast cancer does not have an over-production (overexpression) of these three
receptors, and that is why we call it "triple-negative" breast cancer.
We are trying to find new and better treatments for women with triple negative breast
cancer. We do not know what causes triple negative breast cancers to grow. Other research
studies have shown that "triple negative" breast cancers overexpress different types of
receptors. These receptors might help the cancer to grow.
We will be testing a drug called dasatinib. Dasatinib is a drug that is made by
Bristol-Myers Squibb. It is sold under the name of Sprycel. It was first used to treat
patients with leukemia, a type of blood cancer.
Dasatinib interferes with the growth of some cancers. Dasatinib attaches to the cancer cell
and slows down or stops the cancer cell from growing. It is approved by the Food and Drug
Administration (FDA), but not for the kind of cancer that you have been diagnosed with.
We found this trial at
1
site
Baylor School of Medicine Baylor College of Medicine is a health sciences university that creates...
Click here to add this to my saved trials
